Advances in Diagnostic Imaging for Peripheral Arterial Disease
Transcript of Advances in Diagnostic Imaging for Peripheral Arterial Disease
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
1/21
Authors and Disclosures
Gale L Tang1, Jason Chin2 and Melina R Kibbe2
1VA Puget Sound Health Care System, Division of Vascular Surgery, University of
Washington, Seattle, WA, USA
2Division of Vascular Surgery, Northwestern University Feinberg School of Medicine, 676
North St Clair St, Suite 650, Chicago, IL 60611, USA
Advances in Diagnostic Imaging for
Peripheral Arterial Disease
Gale L Tang; Jason Chin; Melina R Kibbe
Posted: 11/16/2010; Expert Rev Cardiovasc Ther. 2010;8(10):1447-1455. 2010 Expert
Reviews Ltd.
Abstract and Introduction
Abstract
Refinements in both noninvasive and invasive imaging techniques have led to
significant improvements in both the diagnosis and treatment of peripheral arterial
disease. Multiple complementary imaging modalities are available for evaluating these
patients. This article reviews the advantages, disadvantages and recent advances in
the commonly used clinical applications of duplex ultrasonography, magnetic
resonance angiography, computed tomographic angiography, digital subtraction
angiography and intravascular ultrasound for arterial imaging in the lower extremities. It
also discusses experimental imaging techniques more recently applied to peripheral
arterial disease such as PET, hyperspectral imaging and molecular imaging ofatherosclerosis. As more is understood about both lesion and patient characteristics
that affect their response to peripheral interventions, clinician selection of the various
imaging modalities as well as different peripheral interventions will allow for more
effective treatment of patients with peripheral arterial disease.
Introduction
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
2/21
The treatment armamentarium for peripheral arterial disease (PAD) has significantly
changed over the last 20 years with the addition of endovascular therapies to
traditional open bypass procedures. Multiple different endovascular treatment
modalities exist, including balloon angioplasty, cryoplasty, stenting and atherectomy,
including laser, excisional and rotational devices. Preprocedure imaging is increasingly
used to assist in procedural planning, device selection and the determination ofwhether the patient should be treated with an endovascular, open or hybrid approach.
In addition, preprocedure imaging can frequently assist with the minimization of
contrast by allowing a focused endovascular intervention, as well as with the selection
of the safest vascular access site.
Several imaging modalities beyond traditional angiography are available for imaging
the peripheral arterial tree in patients with PAD. These imaging modalities have
evolved and have been refined over time, and have advantages, disadvantages and
contraindications in combination with various patient comorbidities. This article will
focus on the application of duplex ultrasonography, magnetic resonance angiography
(MRA), computed tomographic angiography (CTA), digital subtraction angiography(DSA) and intravascular ultrasound (IVUS) for imaging patients with PAD. The final
section covers some of the current research-based methods of imaging PAD, which
may in the future enter general clinical usage.
Noninvasive Imaging
Duplex Ultrasonography
Duplex ultrasonography has multiple advantages for the assessment of the peripheral
arterial tree. It is the least expensive modality, provides physiologic data in addition toimaging, and can easily be performed in the office as well as in the angiosuite or
operating room, especially with the newer, more portable machines now available. It is
completely noninvasive and does not require the use of potentially nephrotoxic contrast
agents. It has been used successfully as a screening tool to decrease the necessity for
contrast angiography[1] and may also be used as the single preprocedural imaging
modality prior to intervention in approximately 90% of patients (Figure 1).[2,3] The
sensitivity and specificity for the detection and determination of degree of stenosis of
PAD range between 70 and 90%.[4,5]
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
3/21
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
4/21
monophasic spectral waveform. The calcification interrupts the color flow imaging of
the vessel lumen.
As with all ultrasound applications, this imaging modality requires an experienced
vascular technologist or vascular interventionalist to achieve accurate results. A low-
frequency transducer (23.5 mHz) is used for the proximal aortoiliac segment and ahigh-frequency transducer (510 mHz) is used for the lower extremity. A full
examination (infrarenal aorta to pedal arteries) can be time intensive at up to 2 h per
examination, although this may shortened to 2545 min in very experienced hands.[2]
The predictive value of duplex ultrasound for the tibial vessels is not as good as for the
aortoiliac or femoralpopliteal segments; however, patent tibial vessels are
occasionally visualized by arterial duplex but not by DSA, especially in patients with
critical limb ischemia and multilevel disease.[2,5] The pedal arteries may be visualized
using arterial duplex; however, their superficial course renders them easily compressed
by the transducer, which may affect flow velocities. In addition, it is difficult to assess
the entire pedal arch and the quality of the run-off within the foot.[6] Complex collateral
networks can also pose a challenge to the sonographer and make arterial identificationmore difficult. Arterial duplex may be useful for visualizing arterial wall characteristics
that make a target vessel suitable or not for distal bypass, as well as for determining
whether a plaque is a significant risk for distal embolization during an endovascular
intervention. Last, unlike imaging modalities that primarily detect the luminal size of the
artery (MRA and DSA), arterial duplex can accurately determine the actual arterial size,
including the identification of partially thrombosed peripheral aneurysms.
Bowel gas, leg edema, obesity, skin ulceration, vessel calcification and severe
ischemic pain may be limitations to obtaining an accurate arterial duplex examination.
Bowel gas limiting visualization of the aortoiliac segment can be combated by having
the patient present for the first morning examination after being nil per os after
midnight. Leg edema can sometimes be treated by in-hospital leg elevation with
adequate pain control prior to examination. Multiple projections and the use of SonoCT
(ATL, Philips, WA, USA) can be used to assess even severely calcified vessels.[2]
However, the combination of severe tibial calcification and extremely low-flow states
with peak systolic velocity less than 20 cm/s is most likely to render the examination
nondiagnostic.[2]
During intervention, arterial duplex may be used as a substitute for contrast
angiography to assess whether there has been adequate response to intervention by
demonstrating resolution of a peak systolic velocity ratio more than 2.5 (criteriafrequently used for a >50% stenosis). This may obviate the need for multiplanar
angiographic views and decrease the need for contrast. Arterial duplex can provide
objective evidence of whether a dissection in response to balloon angioplasty is flow
limiting or whether elastic recoil has left a hemodynamically significant stenosis,
thereby requiring placement of a stent. Arterial duplex is commonly used for
postintervention monitoring because of its reliability, repeatability, noninvasive nature
and low cost.
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
5/21
Recent advances in ultrasound currently used in arterial duplex scanning include the
improved portability of machines, the use of color-flow and power Doppler to detect
patent but extremely low-flow distal vessels, and sonoCT for improved visual resolution
in B-mode imaging. Contrast-enhanced ultrasound has been demonstrated to improve
agreement between arterial duplex scanning and contrast angiography of the tibial
vessels.[7] However, ultrasound contrast agent availability remains extremely limited inthe USA, as there is no US FDA-approved agent. A newer advance involves 3D
ultrasound. The length and changing depth of the peripheral arterial tree may make this
difficult to apply for the entire arterial duplex examination, but it may be useful to
examine focal lesions. An experimental robotic system has been used in phantom
limbs, but clinical applications have not yet been reported.[8]
Computed Tomographic Angiography
The use of CTA for evaluation of the peripheral arterial tree has significantly advanced
with the advent of increased multidetector scanners. Previous fourth-generation and
16-detector scanners had adequate diagnostic accuracy compared with DSA, butproduced images that were significantly limited by calcification in the tibial arteries.
[9,10] These limitations have largely been overcome by the 64-detector scanner, with a
corresponding decrease in scan time, radiation exposure and contrast volume, and
increase in resolution. Current protocols for 64-detector scanners involve a scan time
of 1520 s, a radiation dose of approximately 5 mSev and a contrast volume of 80130
ml of iodinated contrast.[11,12] A delayed peripheral scan may be necessary to obtain
optimal contrast opacification within the tibial vessels, especially in patients with long-
segment upstream occlusions. Sensitivity and specificity to detect a greater than 50%
stenosis or occlusion using CTA are in the 9599% range.[11,12] LightSpeed Volume
CT (VCT; GE Healthcare, WI, USA) is an example of one of the latest innovations with
64-slice computed tomography technology, capturing images from head to toe in as
little as 10 s. VCT is able to provide wide anatomical detail combined with high-
resolution images (Figure 2). Given the speed of image acquisition, this technology will
be especially useful for sick patients who are not able to breath hold for very long, or
for critically ill trauma patients.
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
6/21
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
7/21
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
8/21
images per examination) generated by MRA. It is important that the imaging volume be
specified to include all vessels of interest, otherwise extra-anatomic bypasses and the
pedal vessels may be accidentally excluded.[15]
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
9/21
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
10/21
Figure 3. Maximum-intensity projection of a magnetic resonance angiogram
composited image of the peripheral arterial system from the abdomen to the feet
using bolus chase technique and acquired in three stations (abdomen/pelvis,
thigh and calf/foot). The patient has a right common and external iliac artery
occlusion, left external iliac and proximal common femoral artery occlusion, as well as
tibial artery disease. Despite multilevel disease, the tibial-level images are free ofvenous contamination and good run-off into the pedal vessels has been included in the
imaging field.
The major limitations to contrast-enhanced MRA remain cost, length of the examination
and inability of the patient to tolerate the examination. It is the most expensive of the
noninvasive modalities. Severely claustrophobic patients frequently cannot tolerate the
60 min examination even with premedication. Patients with pacemakers, automated
implantable cardioverterdefibrillators, certain types of stent grafts and brain aneurysm
clips are excluded from receiving the examination. In the newer, more powerful magnet
machines (3 T), the manufacturers recommend against studying patients with several
other types of intravascular stents (including some coronary stents). MRA is alsolimited in most centers to patients with glomerular filtration rates more than 3035
ml/min secondary to reports of nephrogenic systemic fibrosis developing in patients
with either end-stage renal disease or declining renal function exposed to gadolinium.
[16,17] The risk is likely greater with certain formulations of gadolinium,[17] although
newer ferrous-based contrast agents may eventually prevent this problem. Last,
metallic artifacts from prior intra-arterial stents preclude evaluation of the stented area.
[15] However, an area undergoing rapid evolution is the development of noncontrast
MRA techniques. Many techniques have been described, including phase contrast
imaging, velocity imaging and ECG-triggered flow-sensitive dephasing, to list a few. It
is clear that these newer techniques hold great promise for the future of MRA imaging,but are currently in the developmental or research phase.
Venous contamination of the tibial-level images can be a problem for MRA, especially
in patients with critical limb ischemia and diabetic foot ulcers.[18] Several newer
techniques can be used to reduce venous contamination and increase the diagnostic
utility of the tibial-level images in selected patients. Tibial images may be acquired first
with a separate contrast bolus; the timing bolus can be omitted using newer software
packages that use real-time bolus monitoring to determine the optimal imaging period
after contrast injection. Time-resolved imaging can be useful both to reduce venous
contamination, as well as to demonstrate whether there is a high-grade stenosis or an
occlusion with retrograde filling of the proximal vessel by collaterals. Time-resolvedimaging can also be used to obtain high-quality pedal vessel imaging.[6,19] Steady-
state MRA, which depends on newer gadolinium contrast agents that have prolonged
intravascular half-life, can also be added to tibial-level imaging to improve the
diagnostic quality.[20]
Newer machines feature higher magnet strength (3 T), which can improve spatial
resolution without requiring increased examination length. The field of view is generally
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
11/21
smaller than with 1.5 T units; in taller patients, four imaging stations may be required
for the standard abdomen, pelvis and lower extremity run-off views.[21] Dedicated coil
systems for peripheral arterial imaging are available and also increase spatial
resolution.[22] Last, newer contrast agents are being developed that will also improve
distal imaging.[23]
Invasive Imaging
Digital Subtraction Angiography
Digital subtraction angiography remains the gold standard by which other imaging
modalities are compared. However, it is the most costly of imaging strategies, involves
iodinated contrast administration and radiation exposure, is invasive, and may result in
iatrogenic arterial injury[24] or systemic complication. In addition, many patients suffer
discomfort from laying on the flat, hard endotable for the duration of the procedure, or
the need to keep the access site straight for up to 6 h postprocedure. Early ambulation
(2 h postprocedure) may be possible if a vascular closure device is used; however,
some patients may not be candidates for these devices owing to inappropriate access
site location, antegrade access or significant calcification at the access site.[25,26] As
DSA primarily evaluates the arterial lumen, it may significantly underestimate the
presence of plaque in an artery that has undergone outward adaptive remodeling.
Furthermore, the presence of significant eccentric plaque may be undetected without
special views.[27] Poor technique and long segment occlusions may result in difficulty
viewing patent distal vessels, which may be appropriate for distal bypass for limb
salvage.
Carbon dioxide angiography frequently can be helpful in evaluating patients with renalinsufficiency to limit dye load during evaluation of aortoiliac segments down to the level
of the popliteal arteries. Faster frame rates and specialized equipment is required for
carbon dioxide angiography, which may not be available at all institutions. Detailed
tibial- and pedal-level imaging, especially in the face of long segment proximal
occlusions, generally require contrast.[28] Other strategies for limiting contrast dye and
study time include selective injections, omission of the diagnostic portion of the
examination in favor of a limited examination focused on the pathology identified on
preprocedure noninvasive imaging, and selective use of power injectors.
Additional adjuncts such as smaller sheaths, ultrasound-guided access, and the use of
preprocedure noninvasive imaging to select access site (e.g., brachial access to avoidheavily calcified femoral arteries) will likely decrease access site-related complications
such as hematoma, pseudoaneurysm, arteriovenous fistula, dissection and
embolization, and should be utilized frequently.
Intravascular Ultrasound
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
12/21
There are limited data available regarding the utility of IVUS in peripheral arterial
interventions. It remains questionable whether long-term patency in the infrainguinal
arena can be improved by the use of IVUS during peripheral intervention to the point
where it justifies the additional time spent during the procedure by using another
imaging modality, as well as the US$6001000 additional expense for the IVUS
catheter.[29] Certainly, IVUS can more accurately determine the true arterial diameter,which assists in device size selection, as well as determine whether the stent has been
adequately deployed with good stentarterial wall apposition.[29] Like transcutaneous
arterial duplex, IVUS may be used to judge the efficacy of a peripheral intervention,
allowing minimization of contrast in patients with renal insufficiency. Owing to these
attributes, IVUS is becoming more commonly used during endovascular aneurysm
repair.[30]
Newer catheters utilizing a phased array microtransducer and automated pull-back
systems now allow for improved plaque characterization using 3D reconstruction,
virtual histology and color flow.[31] The automated pull-back system allows for
accurate determination of lesion length as well as 3D reconstruction of the plaquealong the artery. Virtual histology creates a color-coded map of the plaque based on
the intensity and frequency of returning signals, which differ depending on whether the
plaque is primarily fibrous, calcified, fibrofatty or has necrotic lipid core.[31] Heavily
calcified plaques and those with thin fibrous caps and associated ulceration may be
more prone to rupture and distal embolization during intervention. Knowledge of plaque
characteristics may prompt the selective use of distal embolic protection, as well as
direct more intensive medical therapy for those patients found to have unstable
atheromas.[32]
Color-flow IVUS detects differences between two sequential adjacent frames, at 30
frames/s, caused by the movement of echogenic blood particles through the artery.
Although a flow velocity cannot be quantified using this technique, a relative color scale
is used, with orange indicating higher velocity flow than red. This feature can be helpful
when performing interventions without contrast to determine if there is no residual flow-
limiting stenosis, which would cause an elevated velocity.[32]
Alternative Imaging Modalities
Positron Emission Tomography
Positron emission tomography is a recognized nuclear medicine technique foranalyzing nutrient flow and uptake in a variety of tissues, including the brain and heart.
Beyond this, studies have demonstrated its applicability in monitoring skeletal muscle
tissue and quantifying regional muscle blood flow, particularly in the lower extremities
of patients with PAD.[3335] Briefly, PET is a functional imaging modality wherein a
positron-emitting radionuclide is attached to a biologically active molecule such as
glucose or water. The molecule is then introduced into the body, and the system
detects the uptake of the biologically active molecule in imaged tissue via -rays
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
13/21
released by the annihilation of emitted positrons. Currently, the most frequently used
radionuclides for assessing skeletal muscle tissue and regional blood flow in PAD are
fluorodeoxyglucose (FDG) and oxygen-15-water (H2 15O).
No trials have yet been conducted on PET specifically for diagnosis of PAD; however,
studies have returned positive results in its use for assessing the severity of PAD andtissue response to therapeutic interventions. FDG-PET can measure significant
differences in uptake between viable and nonviable skeletal muscle tissue in patients
with PAD.[33] Furthermore, FDG-PET has shown high rates of reproducibility in
measuring inflammation of atherosclerotic plaque lesions in carotid, iliac and femoral
arterial disease.[34] This suggests possible utility for PET in tracking changes in
disease severity over time and after therapy. Studies using H2 15O PET do not show
differences in blood flow determination between PAD patients and control patients at
rest; however, flow reserve (as calculated by the ratio of adenosine-induced changes in
blood flow to baseline flow) shows marked attenuation in PAD patients compared with
healthy controls.[35] PET showed greater resolution in measuring flow reserve than
standard thermodilution and plethysmography techniques.
Although PET is a well-studied imaging modality, diagnostic applications in PAD have
not been a priority for this technology. Most clinical examinations of PET in PAD
patients have focused on its possible use for assessing therapies aimed at increasing
flow and angiogenesis in arterial disease. Compared with currently available
technologies and clinical evaluation for the diagnosis and assessment of PAD, PET
also has significant economic costs associated with it. In the USA, PET studies that
may take up to 12 h are reimbursed by Medicare at a median amount of US$952.83.
[36] However, this may still be cost effective in patients strongly considered for surgery
or prolonged hospitalization.
Hyperspectral Imaging
Hyperspectral imaging, with regards to PAD, is a novel noninvasive technique that can
create a 2D anatomic oxygenation map of imaged tissue. The technology is a method
of scanning spectroscopy based on local chemical composition. A spectral separator is
used to admit varying wavelengths of light to generate a diffuse reflectance spectra for
an imaged object that is compared with standard transmission solutions to calculate
the relative concentrations of oxyhemoglobin and deoxyhemoglobin in each pixel.[37]
Currently available imagers have a pixel size of 0.1 0.1 mm. The wavelengths
admitted by the spectral separator are in the range of 500660 nm to includeoxyhemoglobin and deoxyhemoglobin absorption peaks. In this wavelength range, light
penetrates into the tissue to a depth of approximately 12 mm. Therefore, the
oxygenation information is predominantly from vessels in the subpapillary plexus.[38]
Despite the superficial nature of these oxygenation measurements, data have linked
decreased tissue perfusion measured by hyperspectral imaging with drug-induced
decreases in arterial blood flow analogous to the vascular dysfunction of PAD.[39]
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
14/21
Unpublished clinical studies are underway to confirm differences in oxygenation
measured by hyperspectral imaging in patients with and without known PAD.
This imaging modality is still in its infancy for biomedical applications; however, as the
technology develops it could offer a number of advantages in the diagnostic imaging
and monitoring of PAD. Current imagers record only in the visible spectrum of light atan approximately 12-inch focal distance. This makes hyperspectral imaging completely
noninvasive and noncontact, and thus very well tolerated by patients, especially those
with painful ulcers secondary to vascular disease. In addition, the automated nature of
the imager makes this modality less vulnerable to the inaccuracies possibly associated
with more user-dependent technologies such as Doppler waveform analysis. Since
hyperspectral technology returns a 2D oxygenation map, useful local tissue perfusion
information can be acquired in addition to the more general information inferred about
PAD diagnosis as opposed to current point-measurement oximeters. Values of up to
86% sensitivity, 88% specificity and 96% positive-predictive value have been
demonstrated in studies for the use of hyperspectral imaging in predicting the healing
of diabetic foot ulcers after 6 months.[38,40] Other unpublished studies are also beingconducted regarding the value of hyperspectral technology in imaging PAD patients
perioperatively and for lower extremity amputation planning (Figure 4).
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
15/21
Figure 4. Visual, integrated oxyhemoglobindeoxyhemoglobin, and
deoxyhemoglobin hyperspectral images of the plantar metatarsal angiosome for
a foot (A) without and (B) with peripheral arterial disease . The foot with PAD has
substantially decreased oxyhemoglobin and deoxyhemoglobin values throughout the
angiosome (see scale on the right of each image). Oxydeoxy: Oxyhemoglobin
deoxyhemoglobin; PAD: Peripheral arterial disease.
While hyperspectral imaging presents a potentially advantageous new modality that
could help streamline PAD diagnosis and care, further study is necessary. Published
data are relatively sparse compared with established diagnostic techniques such as the
anklebrachial index and Doppler waveform analysis. Furthermore, no large-scale
studies have been conducted thus far that have included substantial numbers of
patients with PAD, particularly those with PAD severe enough to require surgical
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
16/21
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
17/21
All forms of diagnostic imaging for PAD have evolved and improved over the last few
years. Frequently, the most effective form of imaging is institutionally dependent. One
hospital may have excellent MRA, but inferior CTA, while at another the reverse may be
true. The vascular laboratory and technicians often vary in availability and technical
ability. Differences in generations of equipment, software and radiologic expertise create
these institutional differences. Vascular interventionalists need to be aware of their owninstitutional imaging capabilities, as well as work with the departments involved in
providing the imaging services to improve imaging for patients with PAD.
Five-year View
Spatial resolution will continue to improve with the addition of detectors to multidetector
CT scanners. Furthermore, the development of noncontrast imaging modalities such as
MRA will result in significant advances in vascular imaging by obviating the need for
potentially nephrotoxic or systemically toxic contrast agents. With an increasing
awareness of the hazards associated with cumulative radiation exposure to both the
patient and the clinician, improvements in radiation exposure are likely to be realized.
Cost limitations may drive future adoption of arterial duplex as the primary pre-, during
and postintervention imaging modality. Knowledge gained about how specific lesion
characteristics on preintervention imaging react to various endovascular treatment
modalities will improve the future effectiveness of endovascular therapy for PAD.
Advances in molecular imaging will allow interventions to be targeted to those patients
with vulnerable plaque, as well as determine which patients are more likely to progress
to critical limb ischemia.
Sidebar
Key Issues
Preintervention imaging by duplex ultrasonography, magnetic resonance angiography or
computed tomographic angiography should be part of the standard protocol for all
patients with peripheral arterial disease being considered for intervention.
Institutions differ on the availability and effectiveness of various imaging modalities;
vascular interventionalists need to be familiar with their own institutional capabilities in
order to most effectively apply diagnostic imaging to patients with peripheral arterial
disease.
Effective use of any imaging modality requires close coordination between the vascular
interventionalist and the radiology department or vascular laboratory providing theimaging modality.
Patient tolerance, characteristics (e.g., calcification, obesity or leg edema) and
comorbidities (especially renal insufficiency) will strongly influence which imaging
modality will be the most effective at imaging their arterial tree.
Research imaging modalities such as hyperspectral imaging, PET scanning and
molecular imaging may eventually enter the clinical arena, but will likely be more useful
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
18/21
in assessing patient response to medical therapies directed against atherosclerosis
rather than for use in peripheral interventions.
References
1. Elgzyri T, Ekberg G, Peterson K, Lundell A, Apelqvist J. Can duplex arterial
ultrasonography reduce unnecessary angiography? J. Wound Care 17(11), 497500(2008).
2. Hingorani AP, Ascher E, Marks N et al. Limitations of and lessons learned from clinical
experience of 1,020 duplex arteriography. Vascular16(3), 147153 (2008).
3. Schwarcz TH, Gatz VL, Little S, Geddings CF. Arterial duplex ultrasound is the most
cost-effective, noninvasive diagnostic imaging modality before treatment of lower-
extremity arterial occlusive disease. J. Vasc. Ultrasound33(2), 7579 (2009).
4. Leiner T, Kessels AG, Nelemans PJ et al. Peripheral arterial disease: comparison of
color duplex US and contrast-enhanced MR angiography for diagnosis. Radiology
235(2), 699708 (2005).
5. Favaretto E, Pili C, Amato A et al. Analysis of agreement between duplex ultrasound
scanning and arteriography in patients with lower limb artery disease. J. Cardiovasc.
Med. (Hagerstown) 8(5), 337341 (2007).
6. Langer S, Kramer N, Mommertz G et al. Unmasking pedal arteries in patients with
critical ischemia using time-resolved contrast-enhanced 3D MRA. J. Vasc. Surg. 49(5),
11961202 (2009).
7. Coffi SB, Ubbink DT, Zwiers I, van Gurp JA, Hanson D, Legemate DA. Contrast-
enhanced duplex scanning of crural arteries by means of continuous infusion of
Levovist. J. Vasc. Surg. 39(3), 517522 (2004).
8. Janvier MA, Destrempes F, Soulez G, Cloutier G. Validation of a new 3D-US imaging
robotic system to detect and quantify lower limb arterial stenoses. Conf. Proc. IEEE Eng.
Med. Biol. Soc. 2007, 339342 (2007).9. Hingorani A, Ascher E, Marks N et al. Comparison of computed tomography
angiography to contrast arteriography for patients undergoing evaluation for lower
extremity revascularization. Vasc. Endovasc. Surg. 41(2), 115119 (2007).
10. Willmann JK, Baumert B, Schertler T et al. Aortoiliac and lower extremity arteries
assessed with 16-detector row CT angiography: prospective comparison with digital
subtraction angiography. Radiology236(3), 10831093 (2005).
11. Shareghi S, Gopal A, Gul K et al. Diagnostic accuracy of 64 multidetector computed
tomographic angiography in peripheral vascular disease. Catheter. Cardiovasc. Interv.
75(1), 2331 (2010).
12. Cernic S, Pozzi Mucelli F, Pellegrin A, Pizzolato R, Cova MA. Comparison between 64-
row CT angiography and digital subtraction angiography in the study of lower
extremities: personal experience. Radiol. Med. 114(7), 11151129 (2009).
13. Brockmann C, Jochum S, Sadick M et al. Dual-energy CT angiography in peripheral
arterial occlusive disease. Cardiovasc. Intervent. Radiol. 32(4), 630637 (2009).
14. Bui BT, Miller S, Mildenberger P, Sam A 2nd, Sheng R. Comparison of contrast-
enhanced MR angiography to intraarterial digital subtraction angiography for evaluation
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
19/21
of peripheral arterial occlusive disease: results of a Phase III multicenter trial. J. Magn.
Reson. Imaging31(6), 14021410 (2010).
15. Leiner T. Magnetic resonance angiography of abdominal and lower extremity
vasculature. Top. Magn. Reson. Imaging16(1), 2166 (2005).
16. Weinreb JC, Abu-Alfa AK. Gadolinium-based contrast agents and nephrogenic systemic
fibrosis: why did it happen and what have we learned? J. Magn. Reson. Imaging30(6),12361239 (2009).
17. Wertman R, Altun E, Martin DR et al. Risk of nephrogenic systemic fibrosis: evaluation
of gadolinium chelate contrast agents at four American universities. Radiology 248(3),
799806 (2008).
18. Dinter DJ, Neff KW, Visciani G et al. Peripheral bolus-chase MR angiography: analysis
of risk factors for nondiagnostic image quality of the calf vessels a combined
retrospective and prospective study.AJR Am. J. Roentgenol. 193(1), 234240 (2009).
19. Lim RP, Jacob JS, Hecht EM et al. Time-resolved lower extremity MRA with temporal
interpolation and stochastic spiral trajectories: preliminary clinical experience. J. Magn.
Reson. Imaging31(3), 663672 (2010).
20. Nielsen YW, Eiberg JP, Logager VB, Just S, Schroeder TV, Thomsen HS. Whole-body
magnetic resonance angiography with additional steady-state acquisition of the
infragenicular arteries in patients with peripheral arterial disease. Cardiovasc. Intervent.
Radiol. 33(3), 484491 (2010).
21. Berg F, Bangard C, Bovenschulte H et al. Feasibility of peripheral contrast-enhanced
magnetic resonance angiography at 3.0 Tesla with a hybrid technique: comparison with
digital subtraction angiography. Invest. Radiol. 43(9), 642649 (2008).
22. Kramer H, Michaely HJ, Matschl V, Schmitt P, Reiser MF, Schoenberg SO. High-
resolution magnetic resonance angiography of the lower extremities with a dedicated 36-
element matrix coil at 3 Tesla. Invest. Radiol. 42(6), 477483 (2007).
23. Gerretsen SC, le Maire TF, Miller S et al. Multicenter, double-blind, randomized,intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate
dimeglumine for MR angiography of peripheral arteries. Radiology 255(3), 9881000
(2010).
24. Eslami MH, Csikesz N, Schanzer A, Messina LM. Peripheral arterial interventions:
trends in market share and outcomes by specialty, 19982005. J. Vasc. Surg. 50(5),
10711078 (2009).
25. Bechara CF, Annambhotla S, Lin PH. Access site management with vascular closure
devices for percutaneous transarterial procedures. J. Vasc. Surg. DOI:
10.1016/j.jvs.2010.04.079 (2010) (Epub ahead of print).
26. Engelbert TL, Scholten A, Thompson K, Spivack A, Kansal N. Early ambulation after
percutaneous femoral access with use of closure devices and hemostatic agents. Ann.
Vasc. Surg. 24(4), 518523 (2010).
27. Kashyap VS, Pavkov ML, Bishop PD et al. Angiography underestimates peripheral
atherosclerosis: lumenography revisited. J. Endovasc. Ther. 15(1), 117125 (2008).
28. Madhusudhan KS, Sharma S, Srivastava DN et al. Comparison of intra-arterial digital
subtraction angiography using carbon dioxide by 'home made' delivery system and
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
20/21
conventional iodinated contrast media in the evaluation of peripheral arterial occlusive
disease of the lower limbs. J. Med. Imaging Radiat. Oncol. 53(1), 4049 (2009).
29. Arthurs ZM, Bishop PD, Feiten LE, Eagleton MJ, Clair DG, Kashyap VS. Evaluation of
peripheral atherosclerosis: a comparative analysis of angiography and intravascular
ultrasound imaging. J. Vasc. Surg. 51(4), 933938 (2010).
30. Pearce BJ, Jordan WD Jr. Using IVUS during EVAR and TEVAR: improving patientoutcomes. Semin. Vasc. Surg. 22(3), 172180 (2009).
31. Diethrich EB, Irshad K, Reid DB. Virtual histology and color flow intravascular ultrasound
in peripheral interventions. Semin. Vasc. Surg. 19(3), 155162 (2006).
32. Kohno H, Sueda S. Rupture of a peripheral popliteal artery plaque documented by
intravascular ultrasound: a case report. Catheter. Cardiovasc. Interv. 74(7), 11021106
(2009).
33. El-Haddad G, Zhuang H, Gupta N, Alavi A. Evolving role of positron emission
tomography in the management of patients with inflammatory and other benign
disorders. Semin. Nucl. Med. 34(4), 313329 (2004).
34. Rudd JH, Myers KS, Bansilal S et al. Atherosclerosis inflammation imaging with 18F-
FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and
recommendations. J. Nucl. Med. 49(6), 871878 (2008).
35. Sinusas AJ. Imaging of angiogenesis. J. Nucl. Cardiol. 11(5), 617633 (2004).
36. Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schreyogg J. Economic
evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J.
Nucl. Med. 51(3), 401412 (2010).
37. Greenman RL, Panasyuk S, Wang X et al. Early changes in the skin microcirculation
and muscle metabolism of the diabetic foot. Lancet366(9498), 17111717 (2005).
38. Nouvong A, Hoogwerf B, Mohler E, Davis B, Tajaddini A, Medenilla E. Evaluation of
diabetic foot ulcer healing with hyperspectral imaging of oxyhemoglobin and
deoxyhemoglobin. Diabetes Care 32(11), 20562061 (2009).39. Cancio LC, Batchinsky AI, Mansfield JR et al. Hyperspectral imaging: a new approach to
the diagnosis of hemorrhagic shock. J. Trauma 60(5), 10871095 (2006).
40. Khaodhiar L, Dinh T, Schomacker KT et al. The use of medical hyperspectral technology
to evaluate microcirculatory changes in diabetic foot ulcers and to predict clinical
outcomes. Diabetes Care 30(4), 903910 (2007).
41. Jaffer FA, Libby P, Weissleder R. Molecular and cellular imaging of atherosclerosis:
emerging applications. J. Am. Coll. Cardiol. 47(7), 13281338 (2006).
42. Osborn EA, Jaffer FA. Advances in molecular imaging of atherosclerotic vascular
disease. Curr. Opin. Cardiol. 23(6), 620628 (2008).
43. Nahrendorf M, Zhang H, Hembrador S et al. Nanoparticle PET-CT imaging of
macrophages in inflammatory atherosclerosis. Circulation 117(3), 379387 (2008).44. Jaffer FA, Kim DE, Quinti L et al. Optical visualization of cathepsin K activity in
atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation
115(17), 22922298 (2007).
-
8/6/2019 Advances in Diagnostic Imaging for Peripheral Arterial Disease
21/21
Acknowledgements
Duplex images were provided by Eugene Zierler, Director of the University of
Washington and Harborview Medical Center Vascular Laboratories. MRA images were
provided by Jeffrey Maki, Associate Professor of Radiology at the University of
Washington.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization
or entity with a financial interest in or financial conflict with the subject matter or
materials discussed in the manuscript. This includes employment, consultancies,
honoraria, stock ownership or options, expert testimony, grants or patents received or
pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Expert Rev Cardiovasc Ther. 2010;8(10):1447-1455. 2010 Expert Reviews Ltd.